| | Re: Clinical Proteomics: Cancer Biomarker Discovery Proteomics Lecture
As an update to the lecture, the FDA has approved a biomarker-based test that Dr. Chan helped develop.
In September, the FDA approved the first proteomics-based in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: Vermillion’s OVA1 test (bit.ly/4PFjB9).
OVA1 includes four novel protein biomarkers that were discovered and validated using the SELDI platform, a high-throughput biomarker discovery and protein-profiling tool. The SELDI platform enabled Vermillion to complete a 600-sample validation study in less than six months. Other technologies take the same time to screen 10–15 samples.
For more information about how Vermillion used SELDI, now sold by Bio-Rad, read a case study at bit.ly/SELDI.
Protein Detection Business Unit